Dyadic International Rebrands as Dyadic Applied BioSolutions, Marking Strategic Shift Toward Commercial Bioprocessing Solutions Dyadic International, Inc. (Nasdaq: DYAI), a global biotechnology company known for its proprietary gene expression platforms, has announced a strategic rebrand that reflects its evolution from…
Medimaps Group Launches Next-Generation TBS Osteo Software Across Europe to Revolutionize Osteoporosis Detection Medimaps Group S.A., a Swiss-based global leader in AI-powered bone health solutions, has announced the European launch of its next-generation TBS Osteo Advanced software, following its recent…
Novocure to Present Final PANOVA-3 Data Highlighting Pain and Quality of Life Benefits of TTFields Therapy in Pancreatic Cancer at ESMO GI 2025 Novocure (NASDAQ: NVCR) announced that it will present final secondary endpoint results from its pivotal Phase 3…
Sunshine Biopharma Launches NIOPEG® Biosimilar in Canada, Targeting $10B Biologics Market Sunshine Biopharma Inc. (NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies, and other therapeutic areas, has announced the commercial launch of…
Pneumagen Publishes Promising Phase II Results of Neumifil in Peer-Reviewed Journal, Demonstrating Potential as Broad-Spectrum Antiviral for Respiratory Infections Pneumagen, a clinical-stage biotechnology company focused on developing broad-spectrum antivirals, announced the peer-reviewed publication of its positive Phase II clinical trial…
Alume Biosciences Publishes First-in-Human Data on Bevonescein for Nerve Imaging in Nature Communications Alume Biosciences, a late-clinical stage biotechnology company focused on improving surgical safety through nerve-illuminating technologies, has announced the publication of first-in-human clinical data for its lead compound,…
OXLUMO® (Lumasiran) Secures National Reimbursement in Canada for Treatment of Primary Hyperoxaluria Type 1 Alnylam Canada ULC has announced that OXLUMO® (lumasiran), a first-in-class RNA interference (RNAi) therapeutic, is now funded across Canada through both public and private healthcare plans.…
Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical trial of ART-123, a recombinant human thrombomodulin (rTM), in Japan.…
WHO Unveils “3 by 35” Health Tax Initiative to Combat NCDs and Boost Public Revenue The World Health Organization (WHO) has launched a bold and far-reaching global campaign aimed at saving millions of lives and strengthening public health systems through…
Incyte Grants Equity Awards to Incoming CEO Bill Meury Under Nasdaq Rule 5635(c)(4) Incyte Corporation (Nasdaq: INCY) announced the grant of equity inducement awards to Bill Meury, marking a key milestone as he steps into his new role as the…
Lupin Launches LupinLife as Independent Subsidiary to Strengthen Focus on India’s Self-Care Market Global pharmaceutical leader Lupin Limited has announced a significant strategic move to bolster its consumer healthcare operations. Effective July 1, 2025, Lupin has formally carved out its…
WuXi Biologics Launches WuXiHigh™ 2.0 to Advance High-Concentration Biologic Formulations WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the official launch of WuXiHigh™ 2.0, a next-generation, high-throughput formulation development platform specifically engineered for…
